Senate investigation exposes Gilead’s greed while Kaiser Fam Foundation report shows Part D impact
This if from Ken Saffier, wanting to add it to the ever-growing Big Pharma Shenanigans blogs on drug company malfeasance and greed. per the NY Times, at the time of the release of these extraordinarily expensive Hep C drugs, Gilead admitted that the pricing was totally divorced from their costs but that the drugs were "worth it" because the costs of Hep C care was even more. this extensive Senate Committee investigation, led by a conservative Republican, confirms this. geoff Senator Ron Wyden Press Release December 1, 2015 Wyden-Grassley Sovaldi Investigation Finds Revenue-Driven Pricing Strategy Behind $84,000 Hepatitis Drug 18-Month Investigation Reveals a Pricing and Marketing Strategy Designed to Maximize Revenue with Little Concern for Access or Affordability Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and senior committee member Chuck Grassley, R-Iowa, today released the results of ...